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 In January 2006, Senate Resolution 212 directed the Pennsylvania Legislative Budget and 
Finance Committee: A Joint Committee of the Pennsylvania General Assembly to conduct a 
study of various aspects of colorectal screening.  Researchers at Thomas Jefferson University 
were funded to determine the state’s colorectal cancer burden, describe screening options and 
their cost-effectiveness, determine insurance coverage for screening, and assess screening 
capacity.  The research team completed this policy study using data collected through reviews of 
the scientific literature, contact with leading experts in the field, administration of three statewide 
surveys, collection of data from the Pennsylvania Department of Health, and the Pennsylvania 
Health Care Cost Containment Council.  Findings are summarized below. 
 
Colorectal Cancer Burden and Risk 
 The burden of colorectal cancer (CRC) is substantial in the Commonwealth of 
Pennsylvania.   The state will experience an estimated 8,000 new cases and 2,970 deaths from 
this disease in 2006.1  Pennsylvania colorectal cancer incidence and mortality rates are higher 
than those expected in the nation.  Further, incidence and mortality rates vary considerably 
across the state.  The lifetime risk for being diagnosed with colorectal cancer in the general 
population is approximately 6%.  More than 90% of colorectal cancer cases are diagnosed in 
persons 50 years of age or older.  The risk for being diagnosed with colorectal cancer is greater 
among individuals with a personal or family history of colorectal cancer and or colorectal 
polyps, a personal history of inflammatory bowel disease and certain inherited genetic 
characteristics, e.g., familial adenomatous polyposis (FAP) and hereditary nonpolyposis 
colorectal cancer (HNPCC).2
 
Screening and Cost-Effectiveness 
 Screening for colorectal cancer in the absence of symptoms offers the potential for both 
primary prevention (incidence reduction) by removing pre-cancerous polyps and secondary 
prevention (mortality reduction) by detecting and treating the disease at an early stage. The 
recommended screening modalities are stool blood testing(SBT) every year, flexible 
sigmoidocsopy every five years, annual SBT plus flexible sigmoidoscopy every five years, 
colonoscopy every 10 years, or double contrast barium enema every five years.  Screening with 
colonoscopy is recommended for those at increased risk at age 40, or 10 years before the age at 
which a member of the person’s family was diagnosed with colorectal cancer.3
  
The standard threshold in economic outcomes research holds that an average cost-effectiveness 
ratio (ACER) of less than $50,000 signals a relatively worthwhile economic investment.  An 
ACER compares the total cost of screening to the total number of life years saved.   ACERs for 
the most cost-effective screening strategies are as follows:  ACER for stool blood testing every 
year ranges from $5,980 to $11,632; ACER for combined annual stool blood testing and flexible 
sigmoidoscopy every five years ranges from $13,922 to $24,570; ACER for colonoscopy every 
ten years ranges from $14,181 to $23,570.4  Thus, the use of colorectal cancer screening by 
recommended means is more cost-effective than not screening.  Further, an annual SBT is the 
most cost-effective screening approach, followed by a combination of SBT and flexible 
sigmoidoscopy.  Colonoscopy is less cost-effective than the other two alternatives, although it is 
certainly objectively cost-effective by the standards of economic outcomes research.  
 
Insurance Coverage for Screening 
 Insurance coverage for colorectal cancer screening is not uniform in Pennsylvania.  The 
majority of insurers reported “always” covering the recommended colorectal cancer screening 
tests.  The remaining insurers, however, reported that the screening tests were covered 
“sometimes.”  A small number of insurers restricted coverage for colonoscopy screening to 
enrollees who are at increased risk.  Deductibles and co-payment varied considerably by type of 
screening test.5
 
Colorectal Cancer Treatment Costs 
 In 2005, there were 9,287 hospital admissions in Pennsylvania for which colorectal 
cancer was the primary diagnosis.  Admissions by disease stage were as follows: Stage 1 (1%), 
Stage 2 (54%), Stage 3 and expired (45%).  Treatment costs related to these admissions totaled 
$540,533,844.  Average treatment costs increased in accordance with disease stage: Stage 1 
($36,395), Stage 2 ($54,938), Stage 3 and expired ($62,845).  In 2005, there were also 5,327 
hospital admissions in Pennsylvania for which colorectal cancer was a secondary diagnosis.  
Admissions by disease stage were as follows: Stage 1 and reported history of colorectal cancer 
(1%), Stage 2 (57%), Stage 3 and expired (42%).  Treatment charges related to these admissions 
totaled $222,256,770.   Average treatment charges increased in accordance with disease stage:  
Stage 1 and reported history of CRC ($28,400), Stage 2 ($40,248), and Stage 3 and expired 
($43,944).   Overall, there were a total of 14,614 hospital admissions for which colorectal cancer 
was the primary or secondary diagnosis.  Treatment charges increased in accordance with disease 
stage.  Total charges related to these admissions were $762,790,614.5
Capacity and Demand for Colorectal Cancer Screening 
 A statewide survey of hospitals and ambulatory surgery centers showed that there is 
excess capacity in the state for the performance of colonoscopy procedures.  Analysis of the 
survey data also indicates that flexible sigmoidoscopy screening is not commonly recommended 
or performed but there is substantial excess capacity for the performance of this procedure.  Stool 
blood testing is relatively inexpensive and widely available.  Screening capacity does not present 
a problem.  Using three scenarios, we estimate that if the demand for all colorectal cancer 
screening procedures increased by 2.5%, 5%, or 10% per year, there would still be no capacity 
problem.5   
 
  
Conclusions 
Primary care physicians serve a basic role in facilitating population use of recommended 
colorectal cancer screening tests and follow up of abnormal screening test findings.   Physicians 
most commonly recommend stool blood tests and colonoscopy screening.  Hospitals and 
ambulatory surgery centers routinely provide flexible sigmoidoscopy and colonoscopy screening.  
It appears that sigmoidoscopy is currently used infrequently for colorectal cancer screening 
purposes in Pennsylvania.  The capacity for endoscopy (flexible sigmoidoscopy and 
colonoscopy) screening in the state is substantial, however, and should accommodate increased 
demand without placing a strain on institutions that provide these procedures. 
Any increase in demand for colorectal cancer screening resulting from these efforts is not 
expected to have a significant impact on the pricing structure or safety profile of colonoscopy or 
other screening procedures.  Increases in screening rates can be expected to reduce both the 
incidence and mortality from colorectal cancer.  Higher levels of screening use would be 
expected to reduce the costs of medical care for colorectal cancer.  Increased colorectal cancer 
screening use could substantially reduce the personal and economic burden of colorectal cancer 
for citizens of the Commonwealth. 
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